Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20361743rdf:typepubmed:Citationlld:pubmed
pubmed-article:20361743lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:20361743lifeskim:mentionsumls-concept:C0670896lld:lifeskim
pubmed-article:20361743lifeskim:mentionsumls-concept:C1444754lld:lifeskim
pubmed-article:20361743lifeskim:mentionsumls-concept:C0301872lld:lifeskim
pubmed-article:20361743lifeskim:mentionsumls-concept:C0349590lld:lifeskim
pubmed-article:20361743pubmed:issue9lld:pubmed
pubmed-article:20361743pubmed:dateCreated2010-5-6lld:pubmed
pubmed-article:20361743pubmed:abstractTextOligodeoxynucleotides containing unmethylated CpG motifs act as ligands of Toll-like receptor 9 (TLR9). We previously reported a novel class of TLR9 agonists, referred to as immune-modulatory oligonucleotides (IMOs), in which two 11-mers of the same sequence are attached via their 3'-ends through a 1,2,3-propanetriol linker and contain a synthetic immune-stimulatory motif, Cp7-deaza-dG. In the present study, we have examined the impact of length, nature, and stereochemistry of the linker incorporated in agonists for TLR9 activation. The new linkers studied include (S)-(-)-1,2,4-butanetriol, 1,3,5-pentanetriol, cis,cis-1,3,5-cyclohexanetriol, cis,trans-1,3,5-cyclohexanetriol, 1,3,5-tris(2-hydroxyethyl)isocyanurate, tetraethyleneglycol, and hexaethyleneglycol in place of 1,2,3-propanetriol linker. Agonists with various linkers are studied for TLR9-mediated immune responses in HEK293 cells, human cell-based assays, and in vivo in mice. Results of these studies suggest that C3-C5 linkers, 1,2,3-propanetriol, (S)-(-)-1,2,4-butanetriol, or 1,3,5-pentanetriol, are optimal for stimulation of TLR9-mediated immune responses. Rigid C3 linkers with different stereochemistry have little effect on immune stimulation, while linkers longer than C5 reduced TLR9-mediated immune stimulation.lld:pubmed
pubmed-article:20361743pubmed:languageenglld:pubmed
pubmed-article:20361743pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:citationSubsetIMlld:pubmed
pubmed-article:20361743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20361743pubmed:statusMEDLINElld:pubmed
pubmed-article:20361743pubmed:monthMaylld:pubmed
pubmed-article:20361743pubmed:issn1520-4804lld:pubmed
pubmed-article:20361743pubmed:authorpubmed-author:BhagatLakshmi...lld:pubmed
pubmed-article:20361743pubmed:authorpubmed-author:WangDaqingDlld:pubmed
pubmed-article:20361743pubmed:authorpubmed-author:YuDongDlld:pubmed
pubmed-article:20361743pubmed:authorpubmed-author:KandimallaEka...lld:pubmed
pubmed-article:20361743pubmed:authorpubmed-author:ZhuFu-GangFGlld:pubmed
pubmed-article:20361743pubmed:authorpubmed-author:PuttaMallikar...lld:pubmed
pubmed-article:20361743pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20361743pubmed:day13lld:pubmed
pubmed-article:20361743pubmed:volume53lld:pubmed
pubmed-article:20361743pubmed:ownerNLMlld:pubmed
pubmed-article:20361743pubmed:authorsCompleteYlld:pubmed
pubmed-article:20361743pubmed:pagination3730-8lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:meshHeadingpubmed-meshheading:20361743...lld:pubmed
pubmed-article:20361743pubmed:year2010lld:pubmed
pubmed-article:20361743pubmed:articleTitleImpact of nature and length of linker incorporated in agonists on toll-like receptor 9-mediated immune responses.lld:pubmed
pubmed-article:20361743pubmed:affiliationIdera Pharmaceuticals, Inc., 167 Sidney Street, Cambridge, Massachusetts 02139, USA.lld:pubmed
pubmed-article:20361743pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:20361743lld:chembl